OA11952A - Polymorphs of crystalline (2-benzhydryl-1-azabicycloÄ2,2,2Üoct-3-yl)-5-isopropyl-2-methoxybenzyl)-ammoniumchloride as NK-1 receptor antagonists. - Google Patents
Polymorphs of crystalline (2-benzhydryl-1-azabicycloÄ2,2,2Üoct-3-yl)-5-isopropyl-2-methoxybenzyl)-ammoniumchloride as NK-1 receptor antagonists. Download PDFInfo
- Publication number
- OA11952A OA11952A OA1200100314A OA1200100314A OA11952A OA 11952 A OA11952 A OA 11952A OA 1200100314 A OA1200100314 A OA 1200100314A OA 1200100314 A OA1200100314 A OA 1200100314A OA 11952 A OA11952 A OA 11952A
- Authority
- OA
- OAPI
- Prior art keywords
- dihydrochloride
- crystalline
- anhydrous
- dihydrate
- water
- Prior art date
Links
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title description 4
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title description 4
- 239000002464 receptor antagonist Substances 0.000 title description 4
- 229940044551 receptor antagonist Drugs 0.000 title description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 title description 2
- 229960001040 ammonium chloride Drugs 0.000 title description 2
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 206010047700 Vomiting Diseases 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 229910001868 water Inorganic materials 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 17
- CKQQMPJQZXIYMJ-UHFFFAOYSA-N dihydrate;dihydrochloride Chemical compound O.O.Cl.Cl CKQQMPJQZXIYMJ-UHFFFAOYSA-N 0.000 claims description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- 229940093499 ethyl acetate Drugs 0.000 claims description 8
- 235000019439 ethyl acetate Nutrition 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- 150000004683 dihydrates Chemical class 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 5
- 230000003474 anti-emetic effect Effects 0.000 claims description 4
- 239000002111 antiemetic agent Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000001757 thermogravimetry curve Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003890 substance P antagonist Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 3
- SJSWRKNSCWKNIR-UHFFFAOYSA-N azane;dihydrochloride Chemical compound N.Cl.Cl SJSWRKNSCWKNIR-UHFFFAOYSA-N 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 6
- 239000002002 slurry Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000646 scanning calorimetry Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14023399P | 1999-06-22 | 1999-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA11952A true OA11952A (en) | 2006-04-13 |
Family
ID=22490317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200100314A OA11952A (en) | 1999-06-22 | 2000-06-06 | Polymorphs of crystalline (2-benzhydryl-1-azabicycloÄ2,2,2Üoct-3-yl)-5-isopropyl-2-methoxybenzyl)-ammoniumchloride as NK-1 receptor antagonists. |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US6262067B1 (cs) |
| EP (1) | EP1187834A1 (cs) |
| JP (1) | JP2003502425A (cs) |
| KR (1) | KR20020030280A (cs) |
| CN (1) | CN1390216A (cs) |
| AP (1) | AP2001002367A0 (cs) |
| AR (1) | AR024411A1 (cs) |
| AU (1) | AU767336B2 (cs) |
| BG (1) | BG106205A (cs) |
| BR (1) | BR0011835A (cs) |
| CA (1) | CA2375265A1 (cs) |
| CO (1) | CO5190663A1 (cs) |
| CZ (1) | CZ20014458A3 (cs) |
| DZ (1) | DZ3055A1 (cs) |
| EA (1) | EA004264B1 (cs) |
| EC (1) | ECSP003538A (cs) |
| EE (1) | EE200100698A (cs) |
| HR (1) | HRP20010920A2 (cs) |
| HU (1) | HUP0201694A3 (cs) |
| IL (1) | IL146410A0 (cs) |
| IS (1) | IS6161A (cs) |
| MA (1) | MA26744A1 (cs) |
| MX (1) | MXPA02000033A (cs) |
| NO (1) | NO20016187D0 (cs) |
| NZ (1) | NZ515348A (cs) |
| OA (1) | OA11952A (cs) |
| PA (1) | PA8496701A1 (cs) |
| PE (1) | PE20010322A1 (cs) |
| PL (1) | PL352899A1 (cs) |
| SK (1) | SK18672001A3 (cs) |
| TN (1) | TNSN00137A1 (cs) |
| TR (1) | TR200103688T2 (cs) |
| UY (1) | UY26211A1 (cs) |
| WO (1) | WO2000078759A1 (cs) |
| ZA (1) | ZA200110387B (cs) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6387925B1 (en) * | 1999-06-01 | 2002-05-14 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions |
| US6756379B2 (en) * | 2001-07-26 | 2004-06-29 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
| US6939873B2 (en) * | 2000-07-26 | 2005-09-06 | Taro Pharmaceuticals Industries Limited | Non-sedating barbituric acid derivatives |
| US7683071B2 (en) * | 2000-07-26 | 2010-03-23 | Taro Pharmaceuticals Industries Ltd. | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
| WO2004031191A1 (en) * | 2002-10-04 | 2004-04-15 | Merck Sharp & Dohme Limited | Azabicyclic spiroether derivatives as receptor antagonists |
| AU2003302897C1 (en) * | 2002-12-11 | 2010-07-08 | Taro Pharmaceutical Industries Limited | Method of treating movement disorders using barbituric acid derivatives |
| CA2572797A1 (en) * | 2004-07-02 | 2006-01-12 | Daniella Gutman | A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid |
| EP2081576A4 (en) * | 2006-11-14 | 2010-06-30 | Taro Pharmaceuticals North Ame | METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES |
| UA102128C2 (en) * | 2008-12-05 | 2013-06-10 | Х. Луннбек А/С | Nalmefene hydrochloride dihydrate |
| IL288547B2 (en) * | 2019-06-03 | 2025-10-01 | Biotheryx Inc | Non-hygroscopic crystalline pyrazole compound salts, pharmaceutical preparations thereof and use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005525A1 (en) * | 1988-11-23 | 1990-05-31 | Pfizer Inc. | Quinuclidine derivatives as substance p antagonists |
| CA2102179C (en) * | 1991-05-31 | 1998-10-27 | Fumitaka Ito | Quinuclidine derivatives |
| CA2149242C (en) * | 1992-11-12 | 1998-08-04 | Fumitaka Ito | Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
-
2000
- 2000-05-04 US US09/564,528 patent/US6262067B1/en not_active Expired - Fee Related
- 2000-06-06 CA CA002375265A patent/CA2375265A1/en not_active Abandoned
- 2000-06-06 AP APAP/P/2001/002367A patent/AP2001002367A0/en unknown
- 2000-06-06 PA PA20008496701A patent/PA8496701A1/es unknown
- 2000-06-06 PL PL00352899A patent/PL352899A1/xx not_active Application Discontinuation
- 2000-06-06 MX MXPA02000033A patent/MXPA02000033A/es unknown
- 2000-06-06 EA EA200101179A patent/EA004264B1/ru not_active IP Right Cessation
- 2000-06-06 AU AU47745/00A patent/AU767336B2/en not_active Ceased
- 2000-06-06 EP EP00929745A patent/EP1187834A1/en not_active Withdrawn
- 2000-06-06 HR HR20010920A patent/HRP20010920A2/hr not_active Application Discontinuation
- 2000-06-06 WO PCT/IB2000/000756 patent/WO2000078759A1/en not_active Ceased
- 2000-06-06 TR TR2001/03688T patent/TR200103688T2/xx unknown
- 2000-06-06 SK SK1867-2001A patent/SK18672001A3/sk unknown
- 2000-06-06 HU HU0201694A patent/HUP0201694A3/hu unknown
- 2000-06-06 NZ NZ515348A patent/NZ515348A/en unknown
- 2000-06-06 CN CN00809305A patent/CN1390216A/zh active Pending
- 2000-06-06 KR KR1020017016407A patent/KR20020030280A/ko not_active Ceased
- 2000-06-06 OA OA1200100314A patent/OA11952A/en unknown
- 2000-06-06 EE EEP200100698A patent/EE200100698A/xx unknown
- 2000-06-06 CZ CZ20014458A patent/CZ20014458A3/cs unknown
- 2000-06-06 IL IL14641000A patent/IL146410A0/xx unknown
- 2000-06-06 JP JP2001504925A patent/JP2003502425A/ja active Pending
- 2000-06-06 BR BR0011835-4A patent/BR0011835A/pt not_active IP Right Cessation
- 2000-06-13 CO CO00043885A patent/CO5190663A1/es not_active Application Discontinuation
- 2000-06-20 PE PE2000000613A patent/PE20010322A1/es not_active Application Discontinuation
- 2000-06-20 AR ARP000103053A patent/AR024411A1/es not_active Application Discontinuation
- 2000-06-20 UY UY26211A patent/UY26211A1/es not_active Application Discontinuation
- 2000-06-21 TN TNTNSN00137A patent/TNSN00137A1/fr unknown
- 2000-06-21 MA MA26007A patent/MA26744A1/fr unknown
- 2000-06-21 DZ DZ000113A patent/DZ3055A1/xx active
- 2000-06-22 EC EC2000003538A patent/ECSP003538A/es unknown
-
2001
- 2001-11-13 IS IS6161A patent/IS6161A/is unknown
- 2001-12-10 BG BG106205A patent/BG106205A/bg unknown
- 2001-12-18 NO NO20016187A patent/NO20016187D0/no not_active Application Discontinuation
- 2001-12-19 ZA ZA200110387A patent/ZA200110387B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1180696A (en) | Method for producing chemical compounds | |
| MX2007001854A (es) | Hidratos de polimorfos de 4-[[(7 -r)-8- ciclopentil-7 -etil-5, 6, 7, 8-tetrahidro-5 -metil-4-6 -oxo-2-piperidinil] amino]-3 -metoxi-n- (1-metil-4 -piperidinil)-benzamida, metodos para la produccion de los mismos, y uso de los mismos como medicamentos | |
| OA11952A (en) | Polymorphs of crystalline (2-benzhydryl-1-azabicycloÄ2,2,2Üoct-3-yl)-5-isopropyl-2-methoxybenzyl)-ammoniumchloride as NK-1 receptor antagonists. | |
| US5143935A (en) | Benzamide derivatives | |
| SK282044B6 (sk) | (r)-5-bróm-n-(1-etyl-4-metylhexahydro-1h-1,4-diazepin-6-yl)-2- metoxy-6-metylamino-3-pyridínkarboxamid, spôsob prípravy, medziprodukt a farmaceutický prostriedok, ktorý ho obsahuje | |
| WO1994022843A1 (en) | 2-substituted morpholine and thiomorpholine derivatives as gaba-b antagonists | |
| AU767334B2 (en) | Polymorphs of a crystalline azabicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions | |
| US6387925B1 (en) | Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions | |
| EP0240986B1 (en) | D-nor-7-ergoline derivatives, process for preparing them, pharmaceutical composition and use | |
| US4764517A (en) | 8α-(N,N-diethylsulfamoylamino)-6-n-propyl ergoline useful as a prolactin secretion inhibitor, anti-parkinson, anti-depressant agent | |
| EP0333073A2 (en) | N-cycloalkylaminoethylbenzamide derivatives, their synthesis and pharmaceutical preparations | |
| GB2065113A (en) | Ergoline derivatives, their production and pharmaceutical compositions containing them | |
| HK1050360A (en) | Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2]oct-3yl)-(5-iso-propyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists |